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Inflammatory events persist in systemic lupus erythematosus (lupus) despite the use of anti-inflammatory (both
steroidal and non-steroidal) and immunosuppressive drugs leading to delay in the healing/repair process and so
tissue/organ damage continues. The continuation of inflammation in lupus could be attributed to failure of the
resolution process due to deficiency of potent endogenous pro-resolution-inducing molecules such as lipoxin A4
(LXA4). It is likely that progression and flares of lupus and lupus nephritis are due to decreased formation and
release of LXA4. Hence, administration of LXA4 and its analogues could be of benefit in lupus. Furthermore, plasma
and urinary measurement of lipoxins may be used to predict prognosis and response to therapy. It is likely that
lipoxins and other bioactive anti-inflammatory lipids such as resolvins, protectins, maresins and nitrolipids play a
significant role in other auto-immune diseases such as rheumatoid arthritis, type 1 diabetes mellitus and multiple
sclerosis and hence, could be of significant benefit in these diseases.
Keywords: Lupus rheumatoid arthritis, diabetes mellitus, multiple sclerosis, lipoxins, resolvins, protectins, maresins,
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Introduction
Systemic lupus erythematosus (SLE), a disease of
unknown aetiology that is more common in women
than in men, is characterized by non-destructive arthri-
tis/arthralgias, a cutaneous rash, vasculitis, involvement
of the central nervous system (CNS) and renal and car-
diopulmonary manifestations. Although genetic, envir-
onmental and sex hormonal factors have been
implicated in the pathogenesis of SLE (also called as
“lupus”), it is known that several cytokines, nitric oxide
(NO), free radicals, a deranged immune system, a defi-
cient anti-oxidant defenses, and Toll-like receptors have
a significant role both in the initiation and perpetuation
of the inflammatory process observed.
The fundamental process in lupus appears to be ren-
dering DNA and RNA antigenic that leads to the pro-
duction of anti-DNA and anti-RNA antibodies and the
formation of immune complexes. These antibodies and
immune complexes, in turn, trigger both a local and sys-
temic inflammatory response that ultimately leads to
target organ/tissue damage seen in lupus. The suscept-
ibility to develop lupus in a given individual seems to
have, at least, partly a genetic basis though this is still
not very clear. Once the inflammatory process is
triggered, this leads to the production of a variety of
pro-inflammatory cytokines such as interleukin-1 (IL-1),
IL-6, tumor necrosis factor-a (TNF-a), interferons
(IFNs), macrophage migration inhibitory factor (MIF),
HMGB1 (high mobility group B1) and possibly, a reduc-
tion in the elaboration of anti-inflammatory cytokines
such as IL-10, IL-4, and transforming growth factor-b
(TGF-b). This imbalance between the pro- and anti-
inflammatory cytokines coupled with increased secretion
of free radicals such as superoxide anion (O2
-.), hydro-
gen peroxide (H2O2), singlet oxygen, inducible nitric
oxide (iNO), and other reactive oxygen species (ROS) by
activated monocytes, macrophages, polymorphonuclear
leukocytes (PMNL), T cells, Kupffer cells, glial cells in
the brain, and other organ specific reticuloendothelial
cells would ultimately cause target tissue/organ damage
seen in lupus.
I propose that continued inflammatory events seen in
lupus could be due to failure of the resolution of inflam-
mation. Thus, the balance between inflammation and
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resolution is disturbed more in favor of pro-inflamma-
tory events and/or failure of resolution inducing mole-
cules to be produced at the most appropriate time
leading to non-resolution of inflammation. In other
words, even after the inciting agent responsible for the
initiation of inflammation is removed; inappropriate
inflammation continues simply because resolution failed
to occur. This leads to delay in the healing/repair pro-
cess and so tissue/organ damage continues. This may
explain as to why even when these patients are continu-
ing to take anti-inflammatory and immunosuppressive
medicines, target organ damage continues. In view of
this, it is imperative that institution of pro-resolution-
inducing agents needs to be employed to obtain full
remission and restore normal physiological function of
the target tissues/organs in these diseases. Such endo-
genous pro-resolution-inducing molecules include:
lipoxins, resolvins, protectins, maresins, nitric oxide,
nitrolipids, 15 deoxyΔ12-14 PGJ2, PGD2, anti-inflamma-
tory cytokines such as IL-4, IL-10, and some polyunsa-
turated fatty acids (PUFAs).
Based on this hypothesis, it is suggested that progres-
sion and flares of lupus are due to increased production
of pro-inflammatory molecules IL-6, TNF-a, MIF
(macrophage migration inhibitory factor), HMGB1 (high
mobility group box 1), free radicals and lipid mediators
such as prostaglandins (PGs), leukotrienes (LTs) and/or
decreased formation and release of anti-inflammatory
molecules: IL-4, IL-10, TGF-b, and lipoxins, resolvins,
protectins, maresins and nitrolipids.
Metabolism of essential fatty acids with specific reference
to inflammation
Cis-Linoleic acid (LA, 18:2 ω-6) and a-linolenic acid
(ALA, 18:3 ω-3) are essential nutrients since they cannot
be synthesized by the human body and hence are called
as “essential fatty acids” (EFAs). LA is converted to
gamma-linolenic acid (GLA, 18:3, ω-6) by the action of
the enzyme Δ6 desaturase, and GLA is elongated to
form di-homo-GLA (DGLA, 20:3, ω-6), the precursor of
the 1 series of prostaglandins. Δ6 desaturase is the rate-
limiting step in the metabolism of EFAs. DGLA can also
be converted to arachidonic acid (AA, 20:4, ω-6)) by the
action of the enzyme Δ5 desaturase. AA forms the pre-
cursor of 2 series of prostaglandins, thromboxanes and
the 4 series leukotrienes (LTs). ALA is converted to
eicosapentaenoic acid (EPA, 20:5, ω-3) by Δ6 and Δ5
desaturases. EPA forms the precursor of the 3 series of
prostaglandins and the 5 series of LTs. EPA can be
elongated to form docosahexaenoic acid (DHA, 22:6, ω-
3). AA, EPA and DHA also form precursors to a group
of novel compounds: lipoxins, resolvins, protectins and
maresins [1-9] that have anti-inflammatory action. Eico-
sanoids bind to G protein-coupled receptors on many
cell types and mediate virtually every step of inflamma-
tion, are found in inflammatory exudates, and their
synthesis is increased at sites of inflammation. Non-ster-
oidal anti-inflammatory drugs (NSAIDs) such as aspirin
inhibit cyclo-oxygenase (COX) activity and thus, are
believed to bring about their anti-inflammatory action.
Lipoxins, resolvins, protectins and maresins
There are two cyclo-oxygenase enzymes, the constitu-
tively expressed COX-1 and the inducible enzyme COX-
2. Different types of PGs are formed by the action of
COX enzymes depending on the substrate fatty acid
from which they are derived. Different types of PGs
have different actions and sometimes diametrically
opposite actions. For example, PGE2, PGF2a, thrombox-
ane A2 (TXA2), and leukotrienes (LTs) have pro-inflam-
matory actions whereas PGE1 and prostacyclin (PGI2)
show anti-inflammatory actions. Furthermore, the distri-
butions of COX-1 and COX-2 enzymes have restricted
tissue distribution. Platelets contain thromboxane
synthetase, and hence TXA2, a potent platelet-aggrega-
tor and vasoconstrictor, is formed in these cells, whereas
vascular endothelial cells possess PGI2 synthetase but
lack thromboxane synthetase and thus, they form,
mainly, PGI2, a potent platelet anti-aggregator and vaso-
dilator. The balance between TXA2 and PGI2 is impor-
tant in thrombus formation in coronary and cerebral
blood vessels. PGD2, PGE2 and PGF2a, major metabo-
lites of the COX pathway have pro-inflammatory
actions.
There are 3 types of lipoxygenases and are present in
only a few types of cells. 5-lipoxygenase (5-LO), present
in neutrophils, produces 5-HETE, which is chemotactic
for neutrophils, and is converted into leukotrienes
(LTs). LTB4, a potent chemotactic and activator of neu-
trophils, induces aggregation and adhesion of leukocytes
to vascular endothelium, generation of ROS, and release
of lysosomal enzymes. The cysteinyl-containing leuko-
trienes C4, D4, and E4 (LTC4, LTD4, and LTE4) induce
vasoconstriction, bronchospasm, and vascular perme-
ability in venules. LTs are more potent than histamine
in increasing vascular permeability and causing bronch-
ospasm. LTs mediate their actions by binding to
cysteiny leukotreine 1 (CysLT1) and CysLT2 receptors.
Lipoxins (LXs) are generated from AA, EPA and DHA
by transcellular biosynthetic mechanisms involving two
cell populations. Neutrophils produce intermediates in
LX synthesis, and these are converted to LXs by plate-
lets interacting with leukocytes. LXA4 and LXB4 are
generated by the action of platelet 12-lipoxygenase on
neutrophil-derived LTA4. LXs inhibit leukocyte recruit-
ment, neutrophil chemotaxis and adhesion to endothe-
lium [7]. LXs have a negative regulation on LT synthesis
and action and help in the resolution of inflammation.
Das Lipids in Health and Disease 2011, 10:76
http://www.lipidworld.com/content/10/1/76
Page 2 of 8
An inverse relationship generally exists between LXs
and LTs and the balance between these two molecules
appears to be crucial in the determination of degree of
inflammation and its final resolution [4,6].
Aspirin-triggered 15 epimer LXs (ATLs), resolvins and
protectins
The formation of aspirin-triggered 15 epimer LXs
(ATLs) are potent counter regulators of polymorpho-
nuclear neutrophils (PMNs)-mediated injury and acute
inflammation. Acetylated COX-2 enzyme of endothelial
cells generates 15R-hydroxyeicosatetraenoic acid (15R-
HETE) from AA that is converted by activated PMNs to
the 15-epimeric LXs that have potent anti-inflammatory
properties [2-9]. This cross-talk between endothelial
cells and PMNs leading to the formation of 15R-HETE
and its subsequent conversion to 15-epimeric LXs by
aspirin-acetylated COX-2 is a protective mechanism to
prevent local inflammation on the vessel wall by regulat-
ing the motility of PMNs, eosinophils, and monocytes
[9]. Endothelial cells also oxidize AA, EPA and DHA via
P450 enzyme system to form various hydroxyeicosate-
traenoic acids and epoxyeicosatrienoic acids such as
11,12-epoxy-eicosatetraenoic acid(s) that have many bio-
logical actions that include blocking endothelial cell acti-
vation, while non-enzymatic oxidation products of EPA
inhibit phagocyte-endothelium interaction and suppress
the expression of adhesion molecules [10-15].
Akin to the formation of 15R-HETE and 15-epimeric
LXs from AA, similar compounds are also formed from
EPA and DHA. In the presence of aspirin, activated
COX-2 of human endothelial cells converts EPA to
18R-HEPE, 18-HEPE, and 15R-HEPE. Activated human
PMNs, in turn, converted 18R-HEPE to 5,12,18R-tri-
HEPE and 15R-HEPE to 15-epi-LXA5 by their 5-lipoxy-
genase. Both 18R-HEPE and 5,12,18R-triHEPE inhibited
LTB4-stimulated PMN transendothelial migration.
5,12,18R-triHEPE effectively competed with LTB4 for its
receptors and inhibited PMN infiltration suggesting that
it suppresses LT-mediated responses at the sites of
inflammation [4,6,16,17].
The conversion of EPA by human endothelial cells
with upregulated COX-2 treated with ASA of EPA to
15-epi-LX, also termed aspirin-triggered LX [ATL] and
to 18R-hydroxyeicosapentaenoic acid (HEPE) and 15R-
HEPE is interesting. These compounds in turn, are used
by polymorphonuclear leukocytes to generate separate
classes of novel trihydroxy-containing mediators, includ-
ing 5-series 15R-LX(5) and 5,12,18R-triHEPE, which are
potent inhibitors of human polymorphonuclear leuko-
cyte transendothelial migration and infiltration in vivo
(ATL analogue > 5,12,18R-triHEPE > 18R-HEPE). Acet-
aminophen and indomethacin also permitted 18R-HEPE
and 15R-HEPE generation with recombinant COX-2.
The formation of these bioactive lipid mediators via
COX-2-nonsteroidal antiinflammatory drug-dependent
oxygenations and cell-cell interactions may have signifi-
cant therapeutic benefits in inflammation [16,17].
Murine brain cells expressing COX-2 and treated with
aspirin transformed enzymatically DHA to 17R series of
hydroxy DHAs (HDHAs) that, in turn, is converted
enzymatically by PMNs to di- and tri-hydroxy contain-
ing docosanoids [16-19]. The conversion of DHA by
leukocytes, brain, and glial cells to 17S-hydroxy-contain-
ing docosanoids denoted as docosatrienes (the main
bioactive member of the series was 10,17S-docosatriene)
and 17S series resolvins serve as regulators of both leu-
kocytes reducing infiltration in vivo and glial cells block-
ing their cytokine production. These results indicate that
DHA is the precursor to potent protective mediators
generated via enzymatic oxygenations to novel docosa-
trienes and 17S series resolvins that have significant
anti-inflammatory action and participate in the resolu-
tion of inflammatory events.
Similar small molecular weight compounds are also
generated from AA, EPA, and DHA: 15R-hydroxy con-
taining compounds from AA, 18R series from EPA, and
17R-hydroxy series from DHA. All these compounds
have potent anti-inflammatory actions, resolve inflam-
mation and hence are called as “resolvins”. Resolvins
inhibited cytokine generation, leukocyte recruitment,
leukocyte diapedesis, and exudate formation. The forma-
tion of resolvins from AA, EPA, and DHA from acety-
lated COX-2 are generated via transcellular biosynthesis
(e.g. due to cell-cell communication between endothelial
cells and PMNs), and their main purpose appears to be
to suppress inflammation. Resolvins inhibited brain
ischemia-reperfusion injury [18,19]. It is possible that
lipoxins, resolvins and protectins (docosanoids are also
called as protectins since they have neuroprotective
actions) behave as endogenous anti-inflammatory and
cytoprotective molecules. The general cytoprotective
properties that have been attributed to AA, EPA, and
DHA can be related to their conversion to lipoxins,
resolvins and docosanoids (protectins). Hence, any
defect in the synthesis of lipoxins, resolvins and protec-
tins or their inappropriate degradation could lead to
perpetuation of inflammation as seen in lupus and other
rheumatological conditions.
Anti-inflammatory molecule lipoxin A4 is detectable
in urine
LX4, generated by lipoxygenase (LO) transformation of
AA possess potent anti-inflammatory activity in vivo,
and temporal biosynthesis of LX, concurrent with spon-
taneous resolution, has been observed during exudate
formation [8]. Recently, a new extraction technique,
more selective for LX, which abolishes background
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contamination and minimizes the unspecific reading,
was developed. This new method showed that urine
from healthy subjects contains LXA4 [20]. Subsequently,
it was shown [21] that strenuous exercise significantly
increased urinary excretion in healthy volunteers (0.061
± 0.023 vs. 0.113 ± 0.057 ng/mg creatinine; P = 0.028).
These findings confirm that alterations in the urinary
excretion of LXA4 can used as a reflection of changes in
its (LXA4) formation, especially in the kidney, to moni-
tor changes in the systemic and renal inflammatory
lesions.
In a further extension of this work, it was reported
that urinary levels of LXA4 was decreased while that of
cysLTs (cysteinyl leukotrienes) increased in volunteers
aged from 26 to over 100 years leading to a profound
unbalance of the LXA(4)/cysLTs ratio that may be con-
sidered an index of the endogenous anti-inflammatory
potential [22]. These results suggest that endogenous
anti-inflammatory mechanisms become less efficient
with age that could result in increased susceptibility to
inflammatory disorders with advancing age.
Urinary LXA4 is decreased and LTs increased in HSP
nephritis
In a study in which temporal changes of blood and urin-
ary LXA4, LTB4 (leukotriene B4) and urinary LTE4 was
determined in 49 children with Henoch-Schonlein pur-
pura (HSP) in which renal inflammation is known to
occur, it was reported that inverse temporal changes
between gradually increased blood and urinary LXA4
and gradually decreased blood and urinary LTB4 and
urinary LTE4. Furthermore, both 15-S-hydroxyeicosate-
traenoic acid and LXA4 inhibited the LTB4-induced che-
motaxis of leukocytes and release of LTB4 from
leukocytes obtained from the patients in the active
phase of HSP. In 22 children with HSP nephritis, con-
cordant with the gradually increased severity of mesan-
gial proliferation and proteinuria, the glomerular
expressions of 15-lipoxygenase and the levels of urinary
LXA4 gradually decreased and the glomerular expres-
sions of LTC4 synthase and the urinary LTE4 and LTB4
gradually increased. The levels of blood and urinary
LXA4 in patients with HSP nephritis were lower than
those in patients with purpura alone in early resolution
of HSP. The levels of blood and urinary LTB4 and urin-
ary LTE4 in the patients with HSP nephritis were higher
than those in patients with purpura alone in early reso-
lution of HSP. A positive correlation between blood
LTB4 and serum C-reactive protein in 49 children with
HSP was also noted [23]. These data suggest that LTs
play a proinflammatory and profibrotic role in the
pathogenesis of HSP, and insufficiency of LXA4 may be
responsible for the patients with HSP whose illness
become more serious. These results suggest that absence
or decreased levels of LXA4 that acts as a “stop signal”
of inflammatory process may be responsible for the
nephritis seen in HSP.
Anti-inflammatory cytokines IL-4 and IL-10 enhance LXA4
synthesis
In this context, it is noteworthy that anti-inflammatory
cytokines IL-4 and IL-10 trigger the conversion of AA,
EPA and DHA to lipoxins, resolvins, protectins and
maresins suggesting a mechanism by which they are
able to suppress inflammation [24]. For example, IL-4
up-regulated {(it may be noted here that 15-S-HETE (a
15-LO product; LO = lipoxygenase enzyme) and lipoxins
(interaction products between 5-LO and either 12-LO or
15-LO) counteract the proinflammatory actions of leu-
kotrienes} 15-LO gene expression in human leukocytes.
Glomerular 12/15-LO mRNA increased significantly
over controls 24 and 48 hours after nephrotoxic serum
injection then decreased at 72 hours. RNA from nephro-
toxic serum injected glomeruli contained higher levels of
12/15-LO mRNA than that from unstimulated periph-
eral leukocytes, suggesting that 12/15-LO transcription
is up-regulated locally in native and/or infiltrating glo-
merular cells. Glomerular IL-4 mRNA increased mark-
edly 16 hours post-nephrotoxic serum injection, and
was then reduced, suggesting a potential role for T cell-
derived IL-4 in directing the expression of 12/15-LO
during glomerulonephritis. This suggested tandem regu-
lated in vivo gene expression for IL-4 and LO, both of
which promote counter-inflammatory influences in
immune complex-mediated injury.
Balance between LXA4 and LTs determines the degree of
systemic and glomerular inflammation
The 5-lipoxygenated metabolites of AA, the leukotrienes,
are major mediators of early glomerular hemodynamic
and structural deterioration during experimental glomer-
ulonephritis that are generated largely by infiltrating leu-
kocytes, but can also occur by intrinsic glomerular cells
via transcellular metabolism of intermediates. In animal
models of glomerulonephritis and other renal pathologic
states, leukotrienes have been shown to exert adverse
effects in the glomerulus. LTB4 augments neutrophil infil-
tration, and LTC4 and LTD4 mediate potent vasocon-
strictor effects on the glomerular microcirculation.
Selective blockade of the 5-lipoxygenase pathway
produced a significant amelioration of the deterioration
of renal hemodynamic and structural parameters.
On the other hand, 15-S-hydroxyeicosatetraenoic acid
(15-S-HETE), the immediate product of arachidonate 15-
lipoxygenase, and the lipoxins, which are produced by
sequential 15- and 5- or 5- and 12-lipoxygenation of AA
are also generated in the course of glomerular injury that
antagonize leukotriene-induced neutrophil chemotaxis
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and lipoxin A4 antagonized the effects of LTD4 and LTC4
on the glomerular microcirculation. Thus, the contrasting
effects of 5- and 15-lipoxygenase products represent
endogenous pro- and anti-inflammatory influences that
ultimately determine and regulate the extent and severity
of glomerular inflammation [25-28].
These results are in favor of the proposal that anti-
inflammatory cytokines IL-4 and IL-10 induce the
expression and synthesis of anti-inflammatory lipid
mediators lipoxins, resolvins, protectins and maresins in
addition to their ability to suppress the production of
pro-inflammatory cytokines such as IL-2, IL-6, TNF-a,
MIF and HMGB1 and LTs.
PUFAs and lipoxins bind to GPCR to suppress
inflammation
It is noteworthy that monocytes and macrophages
express an extensive repertoire of G protein-coupled
receptors (GPCRs) that regulate inflammation and
immunity. A number of GPCRs (e.g. Edg5, P2ry2 and
6) have been reported to be expressed by macrophages,
and two cell types closely related to macrophages
(osteoclasts and dendritic cells), whereas Gpr84 expres-
sion was largely restricted to macrophage populations
and granulocytes [29]. It is now apparent that many
PUFAs, especially AA, EPA and DHA and their meta-
bolites such as eicosanoids, lipoxins, resolvins, protec-
tins and maresins also function directly as agonists at a
number of G protein-coupled receptors (GPCRs). Tis-
sue distribution studies and siRNA knock-down experi-
ments have indicated key roles for these GPCRs in
glucose homeostasis, adipogenesis, leukocyte recruit-
ment and inflammation [30]. A recent study showed
that the G protein-coupled receptor 120 (GPR120)
functions as a ω-3 fatty acid receptor/sensor. Stimula-
tion of GPR120 with ω-3 fatty acids (EPA and DHA)
induced broad anti-inflammatory effects in monocytic
RAW 264.7 cells and in primary intraperitoneal macro-
phages. All of these effects were abrogated by GPR120
knockdown. The ω-3 fatty acid treatment not only
inhibited inflammation but also enhanced systemic
insulin sensitivity in wild-type mice, but was without
effect in GPR120 knockout mice. These results suggest
that GPR120 is a functional ω-3 fatty acid receptor/
sensor and mediates potent insulin sensitizing and
antidiabetic effects in vivo by repressing macrophage-
induced tissue inflammation [31]. Thus, it is likely that
PUFAs and their anti-inflammatory products such as
lipoxins, resolvins, protectins and maresins inhibit the
production of various pro-inflammatory molecules
including MIF and HMGB1 and thus, suppress inflam-
mation in diseases such as lupus and rheumatoid
arthritis.
Hypothesis
A deficiency of LXA4 and excess of LTs may be responsible
for lupus/lupus nephritis
Based on the evidences presented above and the role of
LXA4 and LTs in inflammation, it is quite logical to sug-
gest that a deficiency of LXA4 and/or an excess of LTs
initiate and perpetuate systemic and renal inflammation
in lupus. Since, it is possible to estimate these com-
pounds in the urine; I propose that progression and
flares of lupus and lupus nephritis are due to decreased
production of LXA4 and enhanced production of LTs by
the renal tissue and/or infiltrating leukocytes and
macrophages. These molecules can be detected and esti-
mated in the urine [20-23] as already discussed above.
Furthermore, the urinary levels of LXA4 and LTs may
also be used to predict prognosis and response to treat-
ment. If the urinary LXA4 levels revert to normal or are
slowly increasing with and without decrease in urinary
levels of LTs, it can be considered as an indication that
the patient is responding to treatment and that both
systemic and renal lesions of lupus are ameliorating.
The urinary levels of LXA4 and LTs can be compared to
their plasma concentrations; and to serum urea, creati-
nine and urinary protein values and wherever possible
to renal biopsy findings to know the progress of renal
lupus disease.
Since resolvins, protectins and maresins are also anti-
inflammatory lipid molecules derived from EPA and
DHA and have a role in the resolution of inflammation,
it is predicted that they may also have the same signifi-
cance as that of lipoxins in lupus nephritis. To measure
resolvins, protectins and maresins in urine reliable
methods are yet to be developed. If they are developed,
then it is worthwhile to measure the urinary levels of
resolvins, protectins and maresins in addition to lipoxins
in the urine of patients with lupus and lupus nephritis
to predict prognosis and response to treatment.
Decrease in their levels in the urine indicates continued
inflammation and renal damage whereas enhancement
in their levels indicates resolution of inflammation and
amelioration of lupus nephritis.
Therapeutic implications
Based on this hypothesis, it is proposed that LXA4 and
its more stable synthetic analogues and resolvins, pro-
tectins, maresins and their agonists are useful in the
management of lupus, rheumatoid arthritis, type 1 dia-
betes mellitus and other autoimmune diseases. Measure-
ment of plasma and urinary levels of LXA4, resolvins,
protectins and maresins may be used as prognostic mar-
kers in these diseases, while in multiple sclerosis; mea-
surement of cerebrospinal fluid (CSF) levels of LXA4,
resolvins, protectins and maresins can be used as
Das Lipids in Health and Disease 2011, 10:76
http://www.lipidworld.com/content/10/1/76
Page 5 of 8
   (+) 
 
      (-) 
                  
        
                
 













TNF-α, IL-6, MIF, HMGB1 
PLA2 
    iPLA2        sPLA2   cPLA2 






COX-2 5-, 12-, 15-LO 
↓PGE2 ↑PGD2 ↑LXA2 ↑15 deoxyΔ12-14 PGJ2 
Resolution of Inflammation 
Stimulus                                 
Immune complex deposition in tissues 
IL-β1 
↑LXA2 






Exaggeration of Lupus/Type 1 DM/ 
Multiple sclerosis 
Amelioration of Lupus/Type 1 
DM/Multiple sclerosis 
Figure 1 Scheme showing the role of prostaglandins, leukotrienes and lipoxins in lupus and other autoimmune diseases. (-) Indicates
inhibition or suppression of action; (+) Indicates activation or enhancement of action. There are three classes of phospholipases that control the
release of AA and other PUFAs: calcium-independent PLA2 (iPLA2), secretory PLA2 (sPLA2), and cytosolic PLA2 (cPLA2) [40]. Each class of PLA2 is
further divided into isoenzymes for which there are 10 for mammalian sPLA2, at least 3 for cPLA2, and 2 for iPLA2. During the early phase of
inflammation, COX-derived PGs and lipoxygenase-derived LTs initiate exudate formation and inflammatory cell influx [41]. TNF-a causes an
immediate influx of neutrophils concomitant with PGE2 and LTB4 production, whereas during the phase of resolution of inflammation an
increase in LXA4 (lipoxin A4), PGD2 and its product 15deoxyΔ
12-14PGJ2 formation occurs that induces resolution of inflammation with a
simultaneous decrease in PGE2 synthesis that stops neutrophil influx and enhances phagocytosis of debris [42,43]. Thus, there appears to be two
waves of release of AA and other PUFAs: one at the onset of inflammation that causes the synthesis and release of PGE2 and a second at
resolution for the synthesis of anti-inflammatory PGD2, 15deoxyΔ
12-14PGJ2, and lipoxins that are necessary for the suppression of inflammation.
Thus, COX-2 enzyme has both harmful and useful actions by virtue of its ability to give rise to pro-inflammatory and anti-inflammatory PGs and
LXs.Increased type VI iPLA2 protein expression was found to be the principal isoform expressed from the onset of inflammation up to 24 hours,
whereas type IIa and V sPLA2 was expressed from the beginning of 48 hours till 72 hours while type IV cPLA2 was not detectable during the
early phase of acute inflammation but increased progressively during resolution peaking at 72 hours. This increase in type IV cPLA2 was mirrored
by a parallel increase in COX-2 expression [44]5. The increase in cPLA2 and COX-2 occurred in parallel, suggesting a close enzymatic coupling
between these two. Thus, there is a clear-cut role for different types of PLA2 in distinct and different phases of inflammation. Selective inhibition
of cPLA2 resulted in the reduction of pro-inflammatory molecules PGE2, LTB4, IL-1b, and platelet-activating factor (PAF). Furthermore, inhibition of
types IIa and V sPLA2 not only decreased PAF and LXA4 (lipoxin A4) but also resulted in a reduction in cPLA2 and COX-2 activities. These results
suggest that sPLA2-derived PAF and LXA4 induce COX-2 and type IV cPLA2. IL-1b induced cPLA2 expression. This suggests that one of the
functions of IL-1 is not only to induce inflammation but also to induce cPLA2 expression to initiate resolution of inflammation [45,46].Synthetic
glucocorticoid dexamethasone inhibited both cPLA2 and sPLA2 expression, whereas type IV iPLA2 expression is refractory to its suppressive
actions [44,47,48]. Activated iPLA2 contributes to the conversion of inactive pro-IL-1b to active IL-1b, which in turn induces cPLA2 expression that
is necessary for resolution of inflammation.LXs, especially LXA4 inhibit TNF-a-induced production of ILs; promote TNF-a mRNA decay, TNF-a
secretion, and leukocyte trafficking and thus attenuates inflammation.
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markers of disease progression, response to therapy and
its prognosis.
Previously, I showed that AA, EPA and DHA prevented
chemical-induced type 1 DM in experimental animals
[32-34]. Recent studies [35-39] both in experimental ani-
mals and humans confirmed that PUFAs, especially n-3
fatty acids, do prevent type 1 DM. Since AA, EPA and
DHA form precursors to LXs, resolvins, protectins and
maresins, the ability of these fatty acids to prevent DM
can be ascribed to the formation of the anti-inflammatory
lipids [37-39]. Thus, PUFAs and LXs, resolvins, protectins
and maresins are expected to be beneficial in lupus, RA,
multiple sclerosis and other autoimmune diseases
(see Figure 1).
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